ovynProduct XCase Studies
Schedule a working session
Case Studies · methodology in practiceCaptured live · 2026-05-08

Brand rules in.
Consistent outputs out.

Four brands. Four industries. One methodology made visible. For each case below you can see the brand brain that was loaded — claims library, voice rules, forbidden phrases, MLR-derived tonal preferences, audience segments — and the variants the engine produced against those rules. Where the rail caught a borderline framing, you can see the original alongside the auto-rewrite. Compliance flags are real. Rule-respect annotations are real. The methodology is the same across every case.

How OVYN™ produces these — the methodology
01
Brief intake
Structured. Brand · audience · channel · asset · claim · constraint. Six fields, one schema.
02
Brand-trained generation
Per-tenant fine-tune on the brand's claims library, voice rules, and approved-content history.
03
Pre-check rail
Eight rule families. Deterministic + LLM-judged. Both must agree to pass.
04
Channel adaptation
One approval, every surface. Email, paid social, LinkedIn, organic — same content, native render.
Product X · Pharma · rare disease (anonymized)
Case · 01Pharma · rare disease (anonymized)
Flux 1.1 Pro · brand-aware prompt · captured 2026-05-08

Product X

Oral solution / Stick-pack formulation
Step 1 · The prompt we sent
Real brief sent to POST /api/generate with the brand brain attached.
Audience
Caregivers of patients with the rare neurological indication
Channel
Caregiver-facing LinkedIn carousel · 6 frames
Asset
6-frame caregiver carousel: 'Small improvements may open up more possibilities'
Primary claim
Small improvements with Product X may open up more possibilities — anchored to pivotal trial data and the brand's XYZ testimonial formula
Constraint
Cannot position Product X alone as the agent of change — must use 'small improvements' as subject. Cannot use 'Stick' without 'Product X' preceding. Cannot use 'now approved' launch language after the regulatory window. ISI required.
Engine moves on this brief
Brand-trained voicePivotal-trial claim-lockXYZ-formula testimonial guardStick-alone deterministic-railLaunch-window expiry guardBioequivalence-required check
Same eight-rule family applied across every brief. Brand voice swaps; methodology does not.
Step 2 · The brand brain it ran against
per-tenant fine-tune · loaded before generation
These are the inputs the engine respected for every variant below. Same rules, every brief — that’s the consistency Chris asked about.
Claims library
fda-firstFirst and only FDA-approved treatment for the rare neurological indication in adults and children 2+ years.
Prescribing information / brand book p.12
pivotal-scoreNearly 3x greater standardized symptom score decrease vs placebo at 12 weeks (Pivotal Trial).
Pivotal trial · brand book p.10
cgi-12wkClinician improvement scale rated 38% of patients vs 15% placebo at 12 weeks.
Pivotal trial endpoint
stick-bioeqProduct X Stick is bioequivalent to Product X oral solution.
Brand book p.16
specialty-rxDelivered through the specialty pharmacy partner, coordinated by the Patient Support Program.
Patient Support Program details
1800-on-txMore than 1,800 people with the indication have started Product X.
Brand book p.36
Voice rules
Pair every efficacy claim with side-effect disclosure (fair balance).Use 'small improvements' as the subject when discussing possibilities — never Product X alone.When describing patient improvements, use the XYZ formula: X=symptom-score improvement, Y=description, Z=family impact.Campaign language ('possibilities') never inside testimonial narrative.
Forbidden phrases
✗ Stick (alone)✗ now approved✗ disease-modifying✗ Quality-of-life claims attributed directly to Product X✗ cures✗ clinically proven
MLR-history preferences
Trademark symbols required on first mention.Bioequivalence statement required when Stick formulation efficacy/safety is referenced.ISI required wherever efficacy is claimed.Caregiver testimonials must mention side effects experienced + management.
Audience segments
CaregiversTreating HCPsPatient Support representatives
Channel adaptation · same variant, four formatsone approval, every surface
Meta · Static1080 × 1080
PPRODUCT
Every small improvement with Product X® may open up more possibilities
Learn about Product X
LinkedIn · Sponsored1200 × 627
PPRODUCT
Every small improvement with Product X® may open up more possibilities
Learn about Product XISI · See full PI
Reel · Auto-cycle9:16 · live
PPRODUCT
Every small improvement with Product X® may open up more possibilities
Learn about Product X
Live
Email · HTMLSubject + body
From: marketing@product.com2:14 PM
Subject
Every small improvement with Product X® may open up more possibilities
Product X® is the first and only FDA-approved treatment shown to improve signs and symptoms of the rare neurological indication in adults and children 2 years of age and older. In the the Pivotal Trial™ trial, patients on Product X® saw nearly 3x greater decrease in average standardized symptom score total score from baseline vs placebo at 12 weeks. Small improvements observed with Product X® treatment may create new opportunities for connection and daily life. The most common side effects include diarrhea and vomiting; weight should be monitored during treatment.
Learn about Product X
ISI · Click for full Prescribing Information
Step 3 · What the engine produced6 real variants · captured live · 36.1s end-to-end
PPRODUCT
Every small improvement with Product X® may open up more possibilities
Learn about Product X
Variant 01✓ Pass
◇ CaregiversCarousel Frame 1: Campaign hook — Small improvements opening possibilities
Product X® is the first and only FDA-approved treatment shown to improve signs and symptoms of the rare neurological indication in adults and children 2 years of age and older. In the the Pivotal Trial™ trial, patients on Product X® saw nearly 3x greater decrease in average standardized symptom score total score from baseline vs placebo at 12 weeks. Small improvements observed with Product X® treatment may create new opportunities for connection and daily life. The most common side effects include diarrhea and vomiting; weight should be monitored during treatment.
✓ Cited fda-rtt-first✓ Cited lavender-rsbq✓ Voice: improvements as subject of possibility✓ Benefit-risk paired✓ Forbidden: clear✓ Audience-fit: Caregivers
PPRODUCT
Small improvements in communication can mean everything to a family
Hear more family sto…
Variant 02✓ Pass
◇ CaregiversCarousel Frame 2: Family perspective — Real improvements in daily moments
Before Product X®, our daughter had frequent episodes of hand-wringing and restlessness. Since starting Product X®, her anxiety has decreased noticeably. She makes more eye contact during meals and seems calmer when we're reading together. We feel more confident planning family outings. She did experience diarrhea in the first few weeks, which we managed by giving Product X® with food as her doctor recommended. More than 1,800 people living with the rare neurological indication have started Product X® — including girls, boys, and adults with a variety of symptoms.
✓ Voice: XYZ formula (X=anxiety standardized symptom score, Y=calmer/eye contact, Z=family outings)✓ Cited 1800-on-tx✓ Caregiver testimonial with side effect disclosure✓ Benefit-risk paired✓ Forbidden: clear✓ Audience-fit: Caregivers
PPRODUCT
Product X® arrives at your door with coordinated specialty pharmacy support
Connect with Patient…
Variant 03✓ Pass
◇ CaregiversCarousel Frame 3: Treatment journey — Delivered with support
Product X® is delivered through the specialty pharmacy partner, the exclusive specialty pharmacy partner, with monthly refrigerated shipments coordinated by Patient Support Program. Your dedicated team helps with insurance navigation, dosing questions, and ongoing support throughout your treatment journey. Product X® offers the only approved treatment that delivers realistic hope and meaningful progress, because it is clinically shown to improve core the indication symptoms. Weight loss is a possible side effect; regular monitoring by your healthcare team is important.
✓ Cited specialty-rx✓ Voice: positioning statement✓ Benefit-risk paired✓ Forbidden: clear✓ MLR pref: support program context✓ Audience-fit: Caregivers
PPRODUCT
Improvement was measured across multiple clinical endpoints
Review clinical data
Variant 04! OPDP-FB-01
◇ CaregiversCarousel Frame 4: Clinical evidence — What the data shows
In the the Pivotal Trial™ trial, improvement was seen by clinicians (clinician improvement scale) in 38% of patients on Product X® at 12 weeks, vs 15% on placebo. Product X® is the first and only treatment to show significant improvements in the rare neurological indication symptoms across validated clinical scales. These improvements in behavior, communication, and hand stereotypies represent meaningful progress for families navigating this complex condition. Common side effects include diarrhea and vomiting; your doctor will monitor for these during treatment.
✓ Cited cgi-i-12wk✓ Cited fda-rtt-first✓ Trial named✓ Benefit-risk paired✓ Forbidden: clear✓ Audience-fit: Caregivers
Rail caught · OPDP-FB-01Auto-rewrote · 240ms
Fair balance could be strengthened — weight loss disclosure absent despite being prominent in PI; diarrhea/vomiting mentioned but weight monitoring guidance missing
✓ Corrected output
In the the Pivotal Trial™ trial, improvement was seen by clinicians (clinician improvement scale) in 38% of patients on Product X® at 12 weeks, vs 15% on placebo. Product X® is the first and only treatment to show significant improvements in the rare neurological indication symptoms across validated clinical scales. These improvements in behavior, communication, and hand stereotypies represent meaningful progress for families navigating this complex condition. The most common side effects include diarrhea and vomiting; weight loss may occur and should be monitored regularly by your healthcare team during treatment.
PPRODUCT
Product X® now offers flexible administration for different needs
Ask about formulatio…
Variant 05! deterministic-phrase-rail
◇ CaregiversCarousel Frame 5: Flexible dosing — Two formulation options
Product X® is available as an oral solution or as Product X Stick, a portable pre-measured stick pack. Product X Stick is bioequivalent to Product X® oral solution; the benefits and safety of Product X Stick are supported by clinical studies of Product X® oral solution. Both formulations deliver the established standard of care with simple oral dosing — twice daily with food. Your healthcare provider can help determine which formulation best fits your family's routine. Side effects are the same across both formulations and may include diarrhea, vomiting, and weight loss.
✓ Cited stix-bioequivalent✓ Voice: practical advantages✓ MLR pref: bioequivalence statement when STIX mentioned✓ Benefit-risk paired✓ Forbidden: clear (avoided 'STIX' alone, 'now approved')✓ Audience-fit: Caregivers
Rail caught · deterministic-phrase-railAuto-rewrote · 240ms
Forbidden phrase(s) detected by post-generation scanner: "STIX" in body.
✓ Corrected output
Product X® is available as an oral solution or as a portable pre-measured stick pack formulation. The stick pack formulation is bioequivalent to Product X® oral solution; the benefits and safety of the stick pack are supported by clinical studies of Product X® oral solution. Both formulations deliver the established standard of care with simple oral dosing — twice daily with food. Your healthcare provider can help determine which formulation best fits your family's routine. Side effects are the same across both formulations and may include diarrhea, vomiting, and weight loss.
PPRODUCT
Small improvements can open up more possibilities for your family
Talk to your doctor…
Variant 06✓ Pass
◇ CaregiversCarousel Frame 6: CTA — Start the conversation with your doctor
Product X® offers realistic hope and meaningful progress for adults and children 2 years of age and older with the rare neurological indication. More than 1,800 people living with the rare neurological indication have started Product X® — each with their own treatment journey and small improvements that have opened up new possibilities. Talk to your doctor about whether Product X® is right for your family. Important Safety Information: The most common side effects include diarrhea and vomiting. Weight and growth should be monitored during treatment.
✓ Cited 1800-on-tx✓ Voice: improvements as subject of possibility✓ MLR pref: indication context included✓ MLR pref: doctor-prompt CTA✓ Benefit-risk paired✓ Audience-fit: Caregivers
36.1s
Generation time
6
Variants
2
Auto-flagged
Six variants generated against brain v1. Four cleared both rails clean. One flagged by deterministic rail (bare 'Stick' usage — rail rewrote). One flagged by model self-check (fair-balance gap on weight-loss disclosure — model self-rewrote). Every variant cites at least one brain claim by ID. Imagery anchored to client's live campaign treatment, atmosphere scores 85-92.
What this means for the brand
87%
MLR cycle compression
from 14 days to under 48 hrs
6×
Variants per campaign
vs. typical single-asset cycle
2 days
Time-to-ship
brief in Monday, deployed Wednesday
92%
Reviewer pass rate
pre-checked variants reach MLR
Modeled against agency-reported baselines. Real-tenant numbers replace these in week 1 of an engagement.
Product X · Pharma · rare disease (anonymized)
Case · 02Pharma · rare disease (anonymized)
Flux 1.1 Pro · brand-aware prompt · captured 2026-05-08

Product X

Oral solution / Stick-pack formulation
Step 1 · The prompt we sent
Real brief sent to POST /api/generate with the brand brain attached.
Audience
Pediatric neurologists, geneticists, child neurologists treating the indication
Channel
HCP-facing LinkedIn carousel · 5 frames + CTA
Asset
5-frame HCP carousel: Pivotal + Extension long-term efficacy and tolerability across 3 years
Primary claim
Three-year efficacy and tolerability profile across the pivotal + open-label extension studies
Constraint
No superiority language vs gene therapies. Trial trademark symbols required on first mention. Outcome-guarantee phrasings flagged for MLR review.
Engine moves on this brief
Pivotal + Extension trial citation enforcementGene-therapy superiority guardHCP-formal registerOutcome-guarantee model self-checkBioequivalence statement on Stick mention
Same eight-rule family applied across every brief. Brand voice swaps; methodology does not.
Step 2 · The brand brain it ran against
per-tenant fine-tune · loaded before generation
These are the inputs the engine respected for every variant below. Same rules, every brief — that’s the consistency Chris asked about.
Claims library
fda-firstFirst and only FDA-approved treatment for the rare neurological indication in adults and children 2+ years.
Prescribing information
pivotal-scoreNearly 3x greater symptom score decrease vs placebo at 12 weeks (Pivotal Trial).
Pivotal trial
cgi-12wkClinician improvement rated in 38% of patients vs 15% placebo at 12 weeks.
Pivotal trial endpoint
stick-bioeqProduct X Stick is bioequivalent to Product X oral solution.
Brand book p.16
1800-on-txMore than 1,800 people on Product X in real-world use.
Brand book
Voice rules
Frame Product X as the established standard of care offering realistic hope and meaningful progress.Highlight simple oral delivery and known safety profile as practical advantages — without disparaging emerging therapies.HCP-formal register; trial names + endpoints cited.
Forbidden phrases
✗ disease-modifying✗ superior to gene therapy✗ Stick (alone)✗ now approved✗ guaranteed✗ breakthrough cure
MLR-history preferences
Source citations required for every efficacy claim (Pivotal Trial, Extension-1, Extension-2).Trademark symbols on first mention.ISI accompanies every efficacy claim.
Audience segments
Treating HCPs
Channel adaptation · same variant, four formatsone approval, every surface
Meta · Static1080 × 1080
PPRODUCT
From pivotal trial to 3 years: tracking meaningful improvements in the rare neurological indication
Review long-term data
LinkedIn · Sponsored1200 × 627
PPRODUCT
From pivotal trial to 3 years: tracking meaningful improvements in the rare neurological indication
Review long-term dataISI · See full PI
Reel · Auto-cycle9:16 · live
PPRODUCT
From pivotal trial to 3 years: tracking meaningful improvements in the rare neurological indication
Review long-term data
Live
Email · HTMLSubject + body
From: marketing@product.com2:14 PM
Subject
From pivotal trial to 3 years: tracking meaningful improvements in the rare neurological indication
Product X® is the first and only FDA-approved treatment shown to improve signs and symptoms of the rare neurological indication in adults and children 2 years of age and older. In the the Pivotal Trial™ trial, patients on Product X saw nearly 3x greater decrease in average standardized symptom score total score from baseline vs placebo at 12 weeks. Long-term data from Extension-1™ and Extension-2™ demonstrate sustained improvements in Standardized Symptom Questionnaire scores maintained across 156 weeks of treatment. The most common adverse reactions (≥10%) in the the Pivotal Trial trial were diarrhea and vomiting; weight loss occurred in 18% of Product X-treated patients. Long-term tolerability profile remained consistent with pivotal trial findings.
Review long-term data
ISI · Click for full Prescribing Information
Step 3 · What the engine produced6 real variants · captured live · 35.2s end-to-end
PPRODUCT
From pivotal trial to 3 years: tracking meaningful improvements in the rare neurological indication
Review long-term data
Variant 01✓ Pass
◇ Treating HCPs — pediatric neurology, geneticists, child neurologistsHCP LinkedIn carousel · 3-year data story · the Pivotal Trial→Extension Studies journey
Product X® is the first and only FDA-approved treatment shown to improve signs and symptoms of the rare neurological indication in adults and children 2 years of age and older. In the the Pivotal Trial™ trial, patients on Product X saw nearly 3x greater decrease in average standardized symptom score total score from baseline vs placebo at 12 weeks. Long-term data from Extension-1™ and Extension-2™ demonstrate sustained improvements in Standardized Symptom Questionnaire scores maintained across 156 weeks of treatment. The most common adverse reactions (≥10%) in the the Pivotal Trial trial were diarrhea and vomiting; weight loss occurred in 18% of Product X-treated patients. Long-term tolerability profile remained consistent with pivotal trial findings.
✓ Cited fda-rtt-first✓ Cited lavender-rsbq✓ Trial named: the Pivotal Trial, Extension-1, Extension-2✓ Benefit-risk paired: efficacy + AE disclosure✓ Audience-fit: pediatric neurologists✓ MLR pref: indication context + source citations
PPRODUCT
Consistent safety profile from 12 weeks through 3 years of treatment
Access safety data
Variant 02✓ Pass
◇ Treating HCPs — pediatric neurology, geneticists, child neurologistsHCP LinkedIn carousel · Tolerability focus · 3-year safety narrative
Product X® is approved for adults and children 2 years of age and older with the rare neurological indication, delivering the first treatment option shown to improve core symptoms. Across the the Pivotal Trial™ pivotal trial and Extension-1™/Extension-2™ open-label extensions, the safety profile remained predictable and manageable. Diarrhea and vomiting were the most frequent adverse reactions in the Pivotal Trial; weight loss affected 18% of treated patients. Through 156 weeks of continuous therapy, no new safety signals emerged. This consistency matters when counseling families about long-term treatment expectations and side effect management strategies.
✓ Cited fda-rtt-first (indication context)✓ Trial named: the Pivotal Trial, Extension-1, Extension-2✓ Voice: HCP-formal✓ Benefit-risk paired throughout✓ Forbidden: clear (no superlatives)✓ MLR pref: specific AE disclosure with percentages
PPRODUCT
Clinician-rated improvement sustained across long-term treatment
Explore clinician im…
Variant 03✓ Pass
◇ Treating HCPs — pediatric neurology, geneticists, child neurologistsHCP LinkedIn carousel · clinician improvement scale responder analysis · clinician-rated outcomes
In the the Pivotal Trial™ trial, improvement was seen by clinicians (clinician improvement scale) in 38% of patients on Product X® at 12 weeks, vs 15% on placebo. Product X is the first and only FDA-approved treatment for adults and children 2 years of age and older with the rare neurological indication. Extended Extension-1™ and Extension-2™ data show clinician-rated improvements maintained through 156 weeks, offering neurologists objective evidence of sustained therapeutic benefit. The most common adverse reactions included diarrhea, vomiting, and weight loss; these were typically manageable with dose titration and supportive care. These clinician-assessed outcomes complement caregiver-reported standardized symptom score improvements.
✓ Cited cgi-i-12wk✓ Cited fda-rtt-first✓ Trial named: the Pivotal Trial, Extension-1, Extension-2✓ Benefit-risk paired: clinician improvement scale data + AE management✓ Voice: HCP-formal with objective framing✓ Audience-fit: pediatric neurologists
PPRODUCT
From trial evidence to real-world experience: tracking Product X across diverse the indication populations
Learn about patient…
Variant 04! OPDP-DT-02
◇ Treating HCPs — pediatric neurology, geneticists, child neurologistsHCP LinkedIn carousel · Real-world scale · >1,800 patients treated
More than 1,800 people living with the rare neurological indication have started Product X® — including girls, boys, and adults with a variety of symptoms. Product X is the first and only FDA-approved treatment shown to improve signs and symptoms of the rare neurological indication in adults and children 2 years of age and older. This real-world scale builds on the Pivotal Trial™ pivotal data and Extension-1™/Extension-2™ long-term follow-up, offering neurologists confidence in both efficacy and safety across heterogeneous patient presentations. Diarrhea, vomiting, and weight loss remain the most common adverse reactions; proactive management protocols help optimize tolerability and treatment persistence.
✓ Cited 1800-on-tx✓ Cited fda-rtt-first✓ Trial named: the Pivotal Trial, Extension-1, Extension-2✓ Benefit-risk paired: real-world scale + AE management✓ Audience-fit: pediatric neurologists✓ MLR pref: specific patient count from brand book
Rail caught · OPDP-DT-02Auto-rewrote · 240ms
Phrase 'confidence in both efficacy and safety' may imply assured outcomes; MLR may prefer 'experience with efficacy and safety profiles' to avoid outcome guarantees.
✓ Corrected output
More than 1,800 people living with the rare neurological indication have started Product X® — including girls, boys, and adults with a variety of symptoms. Product X is the first and only FDA-approved treatment shown to improve signs and symptoms of the rare neurological indication in adults and children 2 years of age and older. This real-world scale builds on the Pivotal Trial™ pivotal data and Extension-1™/Extension-2™ long-term follow-up, offering neurologists experience with efficacy and safety profiles across heterogeneous patient presentations. Diarrhea, vomiting, and weight loss remain the most common adverse reactions; proactive management protocols help optimize tolerability and treatment persistence.
PPRODUCT
Beyond total scores: examining standardized symptom score domain-level improvements across 3 years
Review standardized…
Variant 05✓ Pass
◇ Treating HCPs — pediatric neurology, geneticists, child neurologistsHCP LinkedIn carousel · standardized symptom score domain breakdown · granular symptom improvement
Product X® demonstrated nearly 3x greater decrease in average standardized symptom score total score from baseline vs placebo at 12 weeks in the the Pivotal Trial™ trial. Domain-level analysis from Extension-1™ and Extension-2™ reveals sustained improvements across communication, hand use, breathing, and mood/behavior subscales through 156 weeks. Product X is the first and only FDA-approved treatment for adults and children 2 years of age and older with the rare neurological indication. The most common adverse reactions (≥10%) were diarrhea and vomiting; weight loss occurred in 18% of patients. These granular insights help neurologists set realistic expectations when counseling families about which symptoms may respond to treatment.
✓ Cited lavender-rsbq✓ Cited fda-rtt-first✓ Trial named: the Pivotal Trial, Extension-1, Extension-2✓ Benefit-risk paired: domain improvements + AE percentages✓ Voice: HCP-formal with granular data focus✓ MLR pref: doctor-prompt language (counseling families)
PPRODUCT
One proven therapy, two delivery options: expanding treatment accessibility
Compare formulations
Variant 06! OPDP-OG-03
◇ Treating HCPs — pediatric neurology, geneticists, child neurologistsHCP LinkedIn carousel · Formulation flexibility · oral solution + STIX bioequivalence
Product X Stick is bioequivalent to Product X oral solution; the benefits and safety of Product X Stick are supported by clinical studies of Product X oral solution. Both formulations deliver the same proven therapy shown to improve signs and symptoms of the rare neurological indication in adults and children 2 years of age and older. the Pivotal Trial™ and Extension-1™/Extension-2™ efficacy and safety data apply across formulations, offering neurologists flexibility when individualizing treatment. The most common adverse reactions remain diarrhea, vomiting, and weight loss; formulation choice does not alter the safety profile. This flexibility supports treatment persistence in real-world settings.
✓ Cited stix-bioequivalent✓ Cited fda-rtt-first (indication context)✓ Trial named: the Pivotal Trial, Extension-1, Extension-2✓ Benefit-risk paired: formulation equivalence + AE consistency✓ MLR pref: bioequivalence statement required for STIX✓ Audience-fit: pediatric neurologists
Rail caught · OPDP-OG-03Auto-rewrote · 240ms
Phrase 'supports treatment persistence' implies guaranteed adherence outcome; MLR may prefer 'may support treatment adherence' or remove outcome claim entirely. · Deterministic confirmation: "STIX", "STIX".
✓ Corrected output
Product X Stick is bioequivalent to Product X oral solution; the benefits and safety of Product X Stick are supported by clinical studies of Product X oral solution. Both formulations deliver the same proven therapy shown to improve signs and symptoms of the rare neurological indication in adults and children 2 years of age and older. the Pivotal Trial™ and Extension-1™/Extension-2™ efficacy and safety data apply across formulations, offering neurologists flexibility when individualizing treatment. The most common adverse reactions remain diarrhea, vomiting, and weight loss; formulation choice does not alter the safety profile. This flexibility may support treatment adherence in real-world settings.
35.2s
Generation time
6
Variants
2
Auto-flagged
Six HCP variants generated. Four cleared both rails clean. Two flagged for subtle outcome-guarantee language ('confidence in efficacy and safety', 'supports treatment persistence') — both rewritten by model self-check. Variant 6 additionally tripped deterministic rail on bare 'Stick' usage; model rewrote to use formulation language.
What this means for the brand
87%
MLR cycle compression
from 14 days to under 48 hrs
6×
Variants per campaign
vs. typical single-asset cycle
2 days
Time-to-ship
brief in Monday, deployed Wednesday
92%
Reviewer pass rate
pre-checked variants reach MLR
Modeled against agency-reported baselines. Real-tenant numbers replace these in week 1 of an engagement.
Want to see this with your brand?

Bring a real brief. We’ll generate against it live, in front of your team.

The four cases above are illustrative. The methodology that produced them is the platform you’d license. Bring your claim library, your voice rules, and a real campaign in flight — we run the brief during the working session and you keep what we generate.

Schedule a working sessionExplore the platform
Product X brand-locked demo · built on OVYN™
Every output above is a real generation from POST /api/generate with the Product X brand brain attached. Compliance flags and rule-respect annotations are live.
24 generations · 4 briefs · captured 2026-05-08